The MAP3K1 Polyclonal Antibody (PAC033584) is a valuable tool for researchers studying the MAP3K1 protein, which plays a key role in signaling pathways involved in cell growth, differentiation, and apoptosis. This antibody is raised in rabbits and is highly specific for human samples, making it ideal for use in Western blot applications. By targeting the MAP3K1 protein, this antibody enables researchers to detect and analyze its expression in various cell types, providing insights into its functions in cellular processes.MAP3K1, also known as mitogen-activated protein kinase kinase kinase 1, is a crucial component in the MAPK signaling pathway, which is essential for cell survival and proliferation.
Dysregulation of MAP3K1 has been linked to various diseases, including cancer and neurological disorders, making it a promising target for therapeutic interventions. By understanding the role of MAP3K1 in these diseases, researchers can develop new strategies for diagnosis and treatment, advancing the field of molecular biology and drug discovery.
Antibody Name:
Map3k1 Antibody (PACO33584)
Antibody SKU:
PACO33584
Size:
50ug
Host Species:
Rabbit
Tested Applications:
ELISA
Recommended Dilutions:
Species Reactivity:
Mouse
Immunogen:
Recombinant Mouse Mitogen-activated protein kinase kinase kinase 1 protein (1216-1493AA)
Component of a protein kinase signal transduction cascade. Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4. Activates CHUK and IKBKB, the central protein kinases of the NF-kappa-B pathway.
MEKK1: a protein kinase of the STE11 family. Phosphorylates and activates MKK4 and -7, which in turn activate JNK1, -2 and -3. Contains 1 RING-type zinc finger. The RING finger domain of MEKK1 exhibits E3 ubiquitin ligase activity toward c-Jun. c-Jun is downregulated in response to osmotic stress via ubiquitination-mediated degradation by the RING finger domain of MEKK1. Overexpressed/overactivated in multiple tumor types. The Mek1/2 inhibitor U0126 blocks export of influenza viral particles and has been suggested as an antiviral treatment. Single mutations at the same point of each gene also associated with cardiofaciocutaneous syndrome, (also linked with Braf and Kras mutations), displaying morphological, cardiac and mental defects. Inhibitors: U0126, CI-1040/PD184352, PD-0325901 (Phase I cancer), ARRY-142886 (Phase 1, cancer).Protein type: Kinase, protein; EC 2.7.11.25; Protein kinase, STE; Ubiquitin conjugating system; Protein kinase, Ser/Thr (non-receptor); Ubiquitin ligase; Ligase; STE group; STE11 familyCellular Component: cell junction; cytoplasm; cytoskeleton; filamentous actin; membraneMolecular Function: cytoskeletal protein binding; JUN kinase binding; JUN kinase kinase kinase activity; MAP kinase kinase kinase activity; mitogen-activated protein kinase binding; mitogen-activated protein kinase kinase binding; protein binding; protein kinase activity; protein kinase binding; protein serine/threonine kinase activity; sphingolipid binding; ubiquitin-protein ligase activityBiological Process: activation of JNK activity; apoptotic mitochondrial changes; camera-type eye development; JNK cascade; morphogenesis of an epithelial sheet; positive regulation of actin filament polymerization; regulation of cell migration; transforming growth factor beta receptor signaling pathway; wound healing